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Geographic variation in drug susceptibility among iso-
lates of Streptococcus pneumoniae has influenced nation-
al treatment guidelines for community-acquired pneumo-
nia. Whether individual hospital susceptibility data provide
reliable and valid information for providers is unclear. We
examined the geographic and temporal variability in hospi-
tal-reported rates of pneumococcal susceptibility. We sur-
veyed all 52 hospitals that provided acute adult care in the
five counties surrounding Philadelphia and collected data
on levels of penicillin susceptibility among all pneumococ-
cal blood isolates from 1998 to 2000.  In 1998, pneumococ-
cal nonsusceptibility to penicillin varied from 0% to 67% of
all blood isolates across the 33 hospitals with >10 isolates
in that year. Hospital location did not correlate with the level
of reported pneumococcal susceptibility (p = 0.8). In addi-
tion, correlations were not significant in reported pneumo-
coccal susceptibility to penicillin within individual hospitals
during the 3 years.  
A
ntimicrobial drug treatment of patients with commu-
nity-acquired pneumonia is largely empirical because
the pathogen is not frequently identified. Even when a bac-
terial pathogen is identified, antimicrobial drug suscepti-
bility information is frequently delayed for a few days,
necessitating empiric treatment decisions. Guidelines for
empirical treatment have been provided by several organi-
zations, emphasizing the selection of agents based on the
probability of specific pathogens in different clinical set-
tings (1–3). One consistent recommendation of all guide-
lines for all clinical settings is that antimicrobial therapy
cover  Streptococcus pneumoniae because it is the most
common bacterial pathogen and among the most virulent.
A number of factors guide the selection of empirical
therapy for patients with community-acquired pneumonia,
including drug efficacy, side effect profile, and ease of
administration. In addition, the recent emergence of
antimicrobial drug resistance among clinical isolates of S.
pneumoniae has raised considerable concern that a number
of drugs historically endorsed by national treatment guide-
lines may no longer be effective. The recommendations to
avoid β-lactams and macrolides in high-risk settings has
not been preceded by clinical studies demonstrating that
drug resistance in vitro translates into clinical treatment
failures (4). Regardless, emerging resistance to penicillins,
tetracyclines, and macrolides has prompted newer versions
of treatment guidelines to recommend abandoning these
therapies in favor of newer therapies, such as fluoro-
quinolones, in settings where the risk for a drug-resistant
pneumococcal infection is high. Given that penicillin-
resistant S. pneumoniae are increasingly multidrug resist-
ant (5), if the risk for penicillin-resistant S. pneumoniae is
high, the risk for resistance to macrolides and tetracyclines
is correspondingly high.
Specific risk factors for infection with penicillin-resist-
ant  S. pneumoniae have not been clearly identified.
Individual risk factors include prior exposure to antibiotics
and exposure to young children in daycare (6), although no
specific rules guide the interpretation of these risk factors.
In addition, awareness of substantial geographic variation
in the proportion of drug-resistant S. pneumoniae has lead
some groups to recommend consideration of regional sus-
ceptibility patterns in the choice of empirical therapy for
community-acquired pneumonia (2). Unfortunately, rou-
tine isolation of S. pneumoniae is highly dependent on the
clinical setting. For example, blood and sputum samples
are rarely sent from outpatient settings (7); thus, local rates
of pneumococcal drug resistance are primarily determined
by the phenotypes of bacteria isolated from sicker patients
who require hospitalization. Whether results from local
hospital microbiology laboratories provide valid informa-
tion for guiding treatment is unclear. 
The specific aims of this study were to compare the
rates of penicillin resistance among pneumococcal blood
isolates across all acute-care hospitals within a five-coun-
ty region of eastern Pennsylvania. We examined the rela-
tionship between pneumococcal resistance, rates of pneu-
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the reliability of individual hospital rates for guiding treat-
ment decisions. Our underlying hypothesis was that indi-
vidual hospital rates of penicillin resistance among clinical
isolates of S. pneumoniae would be poorly correlated
across time and space, emphasizing the inherent dangers in
using individual hospital rates to guide empirical treatment
decisions in the community. 
Methods
Design
This study was a cross-sectional study of penicillin sus-
ceptibility among clinical blood isolates reported at all
acute-care hospitals in the Delaware Valley Case Control
Network (DVCCN). DVCCN is a population-based net-
work of all adult acute-care hospitals in the five
Pennsylvania counties around the metropolitan
Philadelphia region. These counties (Bucks, Montgomery,
Chester, Delaware, and Philadelphia) contain 52 adult
acute-care hospitals serving a population of 3.4 million
residents.
Data Collection
Data were collected during two periods. During the first
data collection, microbiology laboratory supervisors were
contacted by telephone at each area hospital during
January 1999 to collect data on all pneumococcal blood
isolates during the preceding year. Local laboratory per-
sonnel reported cumulative numbers of pneumococcal
blood isolates and the proportion of isolates that were peni-
cillin nonsusceptible for the 12-month period. When avail-
able, laboratories separately reported susceptibility per-
centiles as susceptible, intermediate susceptible, and
resistant; otherwise, the laboratories reported the com-
bined percentile nonsusceptible (intermediate plus resist-
ant). We collected information on unique isolates but did
not confirm that these represented unique episodes of
patient infections. However, we think hospitals generally
reported only one isolate per patient because guidelines
recommend that hospitals report cumulative susceptibility
data on the basis of single isolates per patient per reporting
period (8).
A second data collection was conducted in early 2001.
The same hospital laboratories were contacted by mail
with follow-up telephone calls requesting the same infor-
mation on cumulative numbers of pneumococcal blood
isolates and the proportion of isolates that were penicillin
nonsusceptible for the 12-month period. Data were
requested for 1999 and 2000 separately, if available. 
Analysis
Annual number of pneumococcal blood isolates and
penicillin-susceptibility rates were summarized for each
hospital for each year. Standard National Committee for
Clinical Laboratory Standards (NCCLS) criteria define
three categories of penicillin susceptibility for S. pneumo-
niae: susceptible (MIC <0.1 µg/mL), intermediate suscep-
tible (MIC 0.1–1.0 µg/mL) and resistant (MIC >2.0
µg/mL) (9). Penicillin-nonsusceptible isolates are defined
as intermediate susceptible and resistant isolates com-
bined. For all analyses, we examined the proportion of iso-
lates that were nonsusceptible. We specifically excluded
any hospital site reporting <10 isolates per year as too
unreliable to provide point estimates of resistance rates.
This level is consistent with NCCLS guidelines recom-
mending hospital laboratories report cumulative suscepti-
bility data only for organisms for which there is a mini-
mum of 10 isolates per reporting period (8). Descriptive
statistics were developed for the distributions of suscepti-
bilities and annual pneumococcal isolation rates. Similar to
prior studies of hospital-level variation (10,11), we report
the proportion of hospitals with >5% deviation from the
overall regional mean rate of resistance because lower lev-
els of deviation are unlikely to influence prescribing deci-
sions.
To analyze the reliability of individual hospital rates of
pneumococcal resistance, we examined the correlation of
rates across each of the 3 years of data collection. We
restricted these analyses to those hospitals reporting >10
pneumococcal blood isolates in 1998, 1999, and 2000.
Correlations between any 2 years were calculated with
Spearman’s correlation coefficient, testing the assumption
that pneumococcal susceptibility levels at individual hos-
pitals should be correlated year to year, regardless of
whether overall susceptibility levels for the region were
rising, falling, or remaining constant. In addition, we cal-
culated an intra-class correlation coefficient across all 3
years of data at the hospital level by using a general linear
model for analysis of variance (12).
Next, we tested the assumption that the proportion of
nonsusceptible  S. pneumoniae at each hospital should
demonstrate an underlying geographic clustering. We test-
ed the geographic clustering of pneumococcal resistance
rates with two methods. First, we analyzed whether the
location of each hospital at the county level was associat-
ed with the proportion of nonsusceptible pneumococci by
using the nonparametric Kruskal-Wallis test. Second, we
conducted Geographic Information System (GIS) mapping
to visually judge the spatial distribution of hospital suscep-
tibility rates. Hospitals were geographically assigned lon-
gitude and latitude coordinates on the basis of the hospital
address by using GIS mapping software (Maptitude,
Caliper Corporation, Newton, MA) to display the propor-
tion of nonsusceptible pneumococci at each hospital loca-
tion on the map. Using data from 1998 only, we graphical-
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cocci as a proportional symbol map (bubble plot), where
each hospital location is represented by a circle whose
radius is proportional to the level of penicillin nonsuscep-
tibility among pneumococcal blood isolates.
We tested the null hypothesis that no spatial autocorre-
lation of the nonsusceptibility rates occurred with Moran’s
I statistic, based on a proximity matrix calculated from the
city-block distances between the longitude-latitude coordi-
nate points of hospital addresses. Moran’s I is a spatial
cross-product coefficient that is interpreted similarly to the
Pearson correlation coefficient (13,14). 
Results
For the survey of 1998 susceptibility results, we
received responses from 47 of 52 hospitals in the DVCCN.
However, in two instances, the results from multiple hos-
pitals were combined at a single laboratory and could not
be separated for reporting purposes. Of the 45 laboratories
reporting results, 33 laboratories reported >10 pneumococ-
cal blood isolates during 1998. Among the 33 sites, the
median number of pneumococcal blood isolates during
1998 was 19 (range 10-92). 
Figure 1 displays the frequency distribution of the pro-
portion of isolates with nonsusceptibility to penicillin as
reported by each hospital in 1998. The proportion of non-
susceptible isolates ranged from 0% to 67%, with a mean
proportion of 21%. Sixty-one percent of hospitals were
>5% above or below the mean. If we only included hospi-
tals with >20 pneumococcal isolates in 1998, a total of 16
hospitals would be included in the analysis; the proportion
of nonsusceptible isolates ranged from 0% to 36%, with a
mean proportion of 20%. Fifty-six percent of hospitals
were >5% above or below the mean proportion of nonsus-
ceptible isolates. 
For the 1999 and 2000 survey results, we received
responses from 31 hospital laboratories. Of these, 23 hos-
pital laboratories reported >10 pneumococcal isolates in 1
of the 2 study years. The mean proportion of isolates with
reduced susceptibility to penicillin was 19% in 1999 and
24% in 2000. Fifty-three percent of sites were >5% above
or below the mean in 1999, and 65% of sites were >5%
above or below the mean in 2000. 
The Table summarizes the relationship between each
hospital’s annual proportion of nonsusceptible pneumo-
coccal blood isolates during the 3 years of the study. For
hospitals reporting >10 isolates in 1998, 1999, and 2000
(N = 15), the proportion of nonsusceptible isolates at each
hospital was poorly correlated between any 2 years. For
1998 to 1999, the Spearman correlation coefficient was
–0.07 (p = 0.82), for 1999 to 2000, the Spearman correla-
tion coefficient was 0.28 (p = 0.32), and for 1998 to 2000,
the Spearman correlation coefficient was –0.03 (p = 0.91).
Across all 3 years, the overall intraclass correlation coeffi-
cient was 0.18. 
Location of hospital by county did not correlate with
the proportion of pneumococcal blood isolates nonsuscep-
tible to penicillin (p = 0.45, 0.37, 0.08 in 1998, 1999, and
2000, respectively). Figure 2 is a proportional symbol map
with each hospital location represented by a circle whose
radius corresponds to the proportion of nonsusceptible
pneumococcal blood isolates at each hospital in 1998.
Overall, Figure 2 shows geographic clustering of the 33
hospitals reporting >10 pneumococcal blood isolates in
1998, 14 of which are gathered in Philadelphia, the most
heavily populated county in our five-county study area. No
geographic clustering in the proportion of nonsusceptible
pneumococci isolated at each hospital was evident from
our data. This finding is supported by a Moran correlation
coefficient of –0.01, demonstrating a lack of statistically
significant spatial autocorrelation in the proportion of non-
susceptible hospital pneumococci at hospitals across the
five-county region (p = 0.80). 
Discussion
Pneumococcal drug resistance has increased at a fast
rate. Most resistant isolates now demonstrate reduced sus-
ceptibility to multiple antimicrobial drug classes, including
β-lactams, macrolides, and tetracyclines. However, sub-
stantial geographic variability in the proportion of pneu-
mococci resistant to different antimicrobial drugs at the
international and national levels suggests that the impact of
resistance on empirical treatment decisions may vary
across regions. Indeed, at least one guideline recommends
that the selection of empirical therapy for outpatients with
community-acquired pneumonia should be influenced by
regional antimicrobial drug susceptibility patterns for S.
pneumoniae (2). 
For most physicians, the obvious source of information
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Figure 1. Proportion of penicillin-nonsusceptible pneumococcal
bloodstream infections at hospitals in the Delaware Valley. The
number of hospitals with each reported level of penicillin nonsus-
ceptibility among all pneumococcal bloodstream isolates at each
hospital in 1998 are shown. Penicillin nonsusceptibility was
defined as any isolate with a penicillin MIC >0.1 µg/mL. Hospitals
with <10 isolates in 1998 were excluded.on community-acquired pneumonia is the microbiologic
susceptibility results from their local hospital laboratory.
Hospitals frequently provide this information in the form
of antibiograms, specifically designed to aid in antimicro-
bial drug selection. The validity of this information is
largely unknown. This study demonstrates that substantial
variability exists in hospital-reported rates of pneumococ-
cal drug resistance over a small geographic region and that
the rates at each site are poorly correlated over time. In
addition, using a variety of approaches, we were unable to
demonstrate substantial geographic clustering of the data
at the individual hospital level, suggesting that the individ-
ual hospital rates poorly reflect an underlying rate of resist-
ance in the community. 
Other studies have demonstrated similar heterogeneity
in the proportion of drug-resistant pneumococci reported
by hospitals over small geographic areas. The Centers for
Disease Control and Prevention reported levels of pneu-
mococcal resistance to penicillin among invasive isolates
from all hospitals within the seven regions in the United
States that comprise their Active Bacterial Core
Surveillance program. The proportion of penicillin-non-
susceptible S. pneumoniae ranged from 15.3% to 38.3%
across the seven regions. The proportion of hospitals with-
in each region that were >5% below or above the average
for the region ranged from 35% to 76%. No hospital char-
acteristics, including proportion of isolates from children
or from black patients, predicted deviation from the
regional average (11). More recently, 16 hospitals in
Brooklyn, New York, participated in boroughwide surveil-
lance for S. pneumoniae in 1997 and 1999. Aggregating
the hospitals into the western and eastern ends of the bor-
ough demonstrated a significant difference in the propor-
tion of penicillin-susceptible isolates, 57% versus 75% (p
= 0.046) (15). 
Our hypothesis that individual hospital rates of drug-
resistant  S. pneumoniae should demonstrate geographic
clustering is based on the assumption that rates of resist-
ance should reflect the underlying distribution of drug
resistance in the source community. Prior research has
demonstrated that patients with community-acquired
pneumonia are hospitalized on average <5 miles from their
place of residence (16). Thus, hospitals within the same
geographic region should admit patients with similar
underlying rates of drug resistance. Moreover, if the pneu-
mococcal resistance rates reported by individual hospitals
should be used to guide physician antibiotic prescribing
decisions for patients with community-acquired pneumo-
coccal infections, hospitals serving similar communities
should report similar rates of resistance.
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Table. Annual variation in proportion of penicillin-nonsusceptible isolates at hospitals in the Delaware Valley 
Annual no. blood isolates   % penicillin nonsusceptible  
Site  1998  1999  2000  1998  1999  2000 
A  25  21  26  0  33  27 
B  12  15  17  0  13  29 
C  29  25  29  24  20  28 
D  14  18  12  14  22  8 
E  44  39  28  18  23  25 
F  27  19  20  19  21  20 
G  26  56  35  19  23  17 
H  62  15  22  19  0  27 
I  10  13  12  20  38  50 
J  44  15  32  20  33  16 
K  92  45  87  22  4  8 
L  35  31  30  29  16  20 
M  41  36  34  29  14  38 
N  33  32  35  36  13  9 
O  19  15  19  37  40  47 
Figure 2. Geographic distribution of penicillin nonsusceptibility
among pneumococcal isolates at 33 hospitals in the Delaware
Valley in 1998. The figure is a proportional symbol map (bubble
plot). Each hospital location is represented by a circle with an H in
the center at the corresponding longitude and latitude of the hos-
pital. The radius of the circle is directly proportional to the propor-
tion of penicillin-nonsusceptible pneumococci at each hospital in
1998. The range is 0% to 67%. Hospitals with <10 isolates in 1998
were excluded. An insert magnifies the geographic distribution of
hospitals clustered in the center of Philadelphia. Beyond reflecting true variability in the underlying
community levels of drug resistance, hospital-level varia-
tion in the proportion of penicillin-susceptible pneumococ-
cal isolates reflects at least four phenomena. First, chance
error can create significant variability in hospital-level
results particularly since many hospitals have only a small
number of invasive pneumococcal isolates per year. We
excluded hospitals with <10 isolates in each study year
from our analyses to reduce the role of chance in our find-
ings, but the relatively small number of isolates at each site
undoubtedly contributed to the significant year-to-year
variability and lack of geographic clustering. However, a
minimum of 10 isolates per year is the NCCLS-recom-
mended minimum number of isolates for reporting cumu-
lative antimicrobial susceptibility results for any species in
any reporting period (8). 
Second, variation in testing strategies at individual hos-
pitals may create bias in the proportion of isolates identi-
fied as nonsusceptible if the thresholds for sending micro-
biologic tests vary according to characteristics that are
likely to influence the probability of a drug-resistant infec-
tion. While this may be an important determinant of vari-
ability in drug-susceptibility rates among clinical isolates
from respiratory and sinus samples, we believe that it is
less likely to explain variability in susceptibility rates
among blood isolates since thresholds for sending blood
cultures are more standardized across clinical practices,
particularly in the management of patients hospitalized
with community-acquired pneumonia. 
Third, hospitals may differ in their methodologic
approach and quality assurance for pneumococcal suscep-
tibility testing. However, a study based on a nationwide
College of American Pathologists proficiency survey of
hospital laboratories demonstrated that, while the use of
specific susceptibility tests varies substantially, few major
interpretive errors occurred in assigning the susceptibility
to standardized pneumococcal isolates (17). In addition,
prior studies have found that the results of susceptibility
data generated at local hospital facilities provide a reason-
able surrogate for susceptibility data generated at central-
ized facilities (18).
Finally, geographic proximity of hospitals does not
ensure that the patient populations served by those hospi-
tals come from the same communities. Indeed, substantial
literature has established important variation in hospital
referral patterns that creates diversity in the source of
patient populations among geographically proximate hos-
pitals. Future research will need to consider the role of
referral patterns in explaining some of the hospital-level
variability observed in this and other studies. 
One limitation of this study is our focus on a single geo-
graphic region in eastern Pennsylvania. Patterns and deter-
minants of hospital-level variation in pneumococcal drug
susceptibility may produce different results in other
regions. In addition, because we focused on hospitals pro-
viding adult care, we cannot generalize our results to pedi-
atric hospitals.
Regardless of whether individual hospitals provide
valid information on local levels of pneumococcal suscep-
tibility, variability in these levels is only clinically mean-
ingful if the range of susceptibility crosses some threshold
for the empirical choice of specific antimicrobial drugs.
Currently in the United States, empirical use of penicillins
for the treatment of community-acquired pneumonia is
uncommon relative to the use of fluoroquinolones and
macrolides (19). However, as resistance to these classes of
antimicrobial drugs continues to grow, physicians will
need to determine appropriate thresholds for switching to
yet newer antimicrobial agents. In these settings, valid
information on local rates of pneumococcal drug suscepti-
bility will become increasingly important. Ideally, data
should be derived from large samples reflective of the
region for which the empirical recommendations apply.
Continued research is needed to determine whether sus-
ceptibility data provided by local hospital microbiology
laboratories can ever serve this purpose.
Acknowledgments
The authors acknowledge the valuable contributions of
Emily Cohen, Linda Crossette, M. Annette Hill, and Tonya
Mincer for their help in the collection of data and preparation of
this manuscript; the following laboratory directors and their staff
members whose participation and continued support made this
research  possible: Herbert Auerbach, Ierachmiel Daskal, Stephen
B. Chasko, Albert Keshgegian, Olarae Giger, David Wright, Ru
Lin Ko Tung, Jim Heald, Harvey B. Spector, Lawrence M.
Matthews, Rose M. Kenny, Xiaoli Chen, Ila Mirchandani,
Howard Elefant, Fernando Garcia, Irwin Hollander, Christopher
Emory, Pantaleon Fagel, Paul Edelstein, D.W. Anderson,  Harvey
J. Bellin, Paul Belser, Gary Stopyra, Leonas Bekeris, Dante
DiMarzio, Susan Yaron, Pradeep Bhagat, James Monihan, John
McCormick, David Steinberg,  Zenon Gibas, Helen Kroh,  Allan
Truant, Donald Junkind, Donald Stieritz, and Manjula
Balasubramanian. 
The following hospitals participated in this study: Abington
Memorial Hospital, Albert Einstein Medical Center, Brandywine
Hospital, Bryn Mawr Hospital, Lankenau Hospital, Paoli
Hospital, Central Montgomery Medical Center, Chestnut Hill
Hospital, Chester County Hospital, Crozer Chester Medical
Center, Taylor Hospital, Springfield Hospital, Delaware County
Memorial Hospital, Doylestown Hospital, Elkins Park Hospital,
Jeanes Hospital, Fox Chase Cancer Center, Frankford Hospital
Torresdale Division, Frankford Hospital Bucks County Campus,
Frankford Hospital Frankford Division, Graduate Hospital,
Parkview Hospital, Grand View Hospital, Hahnemann University
RESEARCH
58 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004Hospital, Medical College of Pennsylvania, Holy Redeemer
Hospital and Medical Center, Hospital of the University of
Pennsylvania, Presbyterian Hospital, Mercy Fitzgerald, Mercy
Suburban, Mercy Hospital of Philadelphia, Methodist Hospital,
Montgomery Hospital, Pennsylvania Hospital, Phoenixville
Hospital, Pottstown Memorial Hospital, Riddle Memorial
Hospital, Roxborough Memorial Hospital, Jennersville Regional
Medical Center, St. Agnes Medical Center, St. Luke’s Bethlehem,
St. Mary Medical Center, Temple University Hospital,
Northeastern Hospital, Episcopal Hospital, Thomas Jefferson
University Hospital, Philadelphia VA Medical Center, and
Warminster Hospital.
J.P.M. is supported by an Advanced Research Career
Development Award from the Health Services Research and
Development Service of the Department of Veterans Affairs. This
research was partly supported by grant R01-AI46645 from the
National Institutes of Health.
Dr. Metlay is a research associate and staff physician at the
VA Medical Center in Philadelphia. He is an assistant professor
of medicine and epidemiology at the University of Pennsylvania
School of Medicine. His research focuses on the epidemiology of
drug-resistant pneumococcal infections, particularly among
adults with community-acquired pneumonia.
References
1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA,
Campbell GD, et al. Guidelines for the management of adults with
community-acquired pneumonia. Diagnosis, assessment of severity,
antimicrobial therapy, and prevention. Am J Respir Crit Care Med
2001;163:1730–54.
2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine
MJ. Practice guidelines for the management of community-acquired
pneumonia in adults. Infectious Diseases Society of America. Clin
Infect Dis 2000;31:347–82.
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH.
Canadian guidelines for the initial management of community-
acquired pneumonia: an evidence-based update by the Canadian
Infectious Diseases Society and the Canadian Thoracic Society. The
Canadian Community-Acquired Pneumonia Working Group. Clin
Infect Dis 2000;31:383–421.
4. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections
and the impact of antimicrobial drug resistance. Clin Microbiol Infect
2002;8(Suppl 2):1–11.
5. Whitney CG, Farley MM, Hadler J, Harrison LH, Levau C, Reingold
A, et al. Increasing prevalence of multidrug-resistant Streptococcus
pneumoniae in the United States. N Engl J Med 2000;343:1917–24.
6. Dowell SF, Schwartz B. Resistant pneumococci: protecting patients
through judicious use of antibiotics. Am Fam Physician
1997;55:1647–54, 1657–8.
7. Fine MJ, Stone RA, Singer DE, Coley CM, Marrie TJ, Lave JR, et al.
Processes and outcomes of care for patients with community-
acquired pneumonia: results from the Pneumonia Patient Outcomes
Research Team (PORT) cohort study. Arch Intern Med
1999;159:970–80.
8. National Committee for Clinical Laboratory Standards. Analysis and
presentation of cumulative antimicrobial susceptibility test data;
Approved guidelines. 2002. Report No.: NCCLS document M39-A.
Philadelphia: The Committee; 2002.
9. National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial susceptibility testing: 12th information
supplement. 2002. Report no.: NCCLS document M100-S12.
Philadelphia: The Committee; 2002
10. Schrag SJ, Zell ER, Schuchat A, Whitney CG. Sentinel surveillance:
a reliable way to track antibiotic resistance in communities? Emerg
Infect Dis 2002;8:496–502.
11. Geographic variation in penicillin resistance in Streptococcus pneu-
moniae—selected sites, United States, 1997. MMWR Morb Mortal
Wkly Rep 1999;48:656–61.
12. Fleiss J. The design and analysis of clinical experiments. New York:
John Wiley and Sons; 1986.
13. Fotheringham A, Brunsdon C, Charlton M. Statistical inference for
spatial data. In: Quantitative geography: perspectives on spatial data
analysis. London: Sage Publications; 2000. p. 201–11.
14. Cliff A, Ord J. Spatial autocorrelation: monographs in spatial and
environmental systems analysis. London: Pion; 1973.
15. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus
pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our
doorstep. Emerg Infect Dis 2002;8:594–7.
16. Lave JR, Fine MJ, Sankey SS, Hanusa BH, Weissfeld LA, Kapoor
WN. Hospitalized pneumonia. Outcomes, treatment patterns, and
costs in urban and rural areas. J Gen Intern Med 1996;11:415–21.
17. Doern GV, Brueggemann AB, Pfaller MA, Jones RN. Assessment of
laboratory performance with Streptococcus pneumoniae antimicro-
bial susceptibility testing in the United States: a report from the
College of American Pathologists Microbiology Proficiency Survey
Program. Arch Pathol Lab Med 1999;123:285–9.
18. Chin AE, Hedberg K, Cieslak PR, Cassidy M, Stefonek KR, Fleming
DW. Tracking drug-resistant Streptococcus pneumoniae in Oregon:
an alternative surveillance method. Emerg Infect Dis 1999;5:688–93.
19. Metlay JP, Shea JA, Crossette LB, Asch DA. Tensions in antibiotic
prescribing: pitting social concerns against the interests of individual
patients. J Gen Intern Med 2002;17:87–94.
Address for correspondence: Joshua P. Metlay, 712 Blockley Hall, 423
Guardian Drive, University of Pennsylvania, Philadelphia PA 19104,
USA; fax: 215-573-0198; email: jmetlay@cceb.med.upenn.edu
RESEARCH
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004 59
The opinions expressed by authors contributing to this journal do
not necessarily reflect the opinions of the Centers for Disease
Control and Prevention or the institutions with which the authors
are affiliated.
Search past issues of EID at www.cdc.gov/eid